Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma

간세포암 환자의 고주파열치료 후 종양 재발: 예후인자로서 문맥고혈압

  • Jang, Seong Won (Department of Radiology, Veterans Health Service Medical Center) ;
  • Cho, Yun Ku (Department of Radiology, Veterans Health Service Medical Center) ;
  • Kim, Ju Won (Department of Radiology, Veterans Health Service Medical Center) ;
  • Gil, Je Ryung (Department of Radiology, Veterans Health Service Medical Center) ;
  • Kim, Mi Young (Department of Radiology, Veterans Health Service Medical Center) ;
  • Lee, Young (Department of Research Institute, Veterans Health Service Medical Center)
  • 장성원 (중앙보훈병원 영상의학과) ;
  • 조윤구 (중앙보훈병원 영상의학과) ;
  • 김주원 (중앙보훈병원 영상의학과) ;
  • 길제령 (중앙보훈병원 영상의학과) ;
  • 김미영 (중앙보훈병원 영상의학과) ;
  • 이영 (중앙보훈병원 의학연구소)
  • Received : 2018.05.21
  • Accepted : 2018.06.29
  • Published : 2018.11.01
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the effect of portal hypertension on the tumor recurrence in patients with hepatocellular carcinoma (HCC) and without hepatic decompression following radiofrequency ablation (RFA). Materials and Methods: Treatment-naïve HCC patients within the Milan criteria and with Child-Pugh class A were included in this study, who had performed RFA in our hospital between January 2010 and March 2017. Univariate and multivariate analyses using the Cox proportional hazard model were performed to find the predictors of local or distant tumor recurrence. Results: Overall, 178 patients were included in this study. Median follow-up period was 40.2 months. The difference in the local tumor progression rates depending on the absence or presence of portal hypertension was not statistically significant (p = 0.195). The 1-, 3-, and 5-year distant intrahepatic tumor spread rates were 6.6%, 29.5%, and 537% in patients without portal hypertension, and 23.4%, 51.9%, and 63.6% in patients with portal hypertension, respectively. The difference was statistically significant (p = 0.011). Univariate and multivariate analysis showed that portal hypertension was an independent predictor for distant intrahepatic tumor spread (p = 0.008). Conclusion: For HCC patients with Child-Pugh class A, portal hypertension adversely affected distant intrahepatic tumor progression.

목적: 간기능이 보존된 간세포암 환자에서 간문맥 고혈압이 고주파열치료 후 종양 재발에 미치는 영향을 평가한다. 대상과 방법: 2010년 1월에서 2017년 3월 사이에 Milan criteria 및 Child-Pugh class A를 가진 신규 간세포암 환자 중 본원에서 고주파열치료를 시행한 환자가 본 연구에 포함되었다. 종양 재발에 대한 예측인자를 찾기 위해 Cox proportional hazard model을 이용한 단변량 및 다변량 분석을 수행하였다. 결과: 모두 178명의 환자가 본 연구에 포함되었다. 추적 관찰 기간의 중앙값은 42.8개월이었다. 국소 재발률은 문맥고혈압 여부에 따라 뚜렷한 차이를 유발하지 않았다(p = 0.195). 3년 및 5년 원위부 간내 종양 재발률은 문맥고혈압이 없는 환자의 경우 각각 29.5%와 53.7%, 그리고 문맥고혈압이 있는 환자의 경우 51.9%와 63.6%였으며 두 군 사이의 차이는 통계적으로 유의하였다(p = 0.011). 단변량 및 다변량 분석에서 문맥압항진은 원위부 간내 종양 재발에 대한 독립적인 예측 인자이었다(p = 0.008). 결론: Child-Pugh class A를 가진 간세포암 환자의 경우, 문맥고혈압은 종양 재발에 불량 예후인자로 작용하였다.

Keywords

References

  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750 https://doi.org/10.1056/NEJM199903113401001
  2. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol 2009;33:911-915 https://doi.org/10.1016/j.gcb.2009.06.001
  3. Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, et al. $p38{\alpha}$ inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res 2013;73:215-224 https://doi.org/10.1158/0008-5472.CAN-12-1602
  4. Kim MY, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2009;21:1241-1246 https://doi.org/10.1097/MEG.0b013e32832a21c1
  5. Thabut D, Moreau R, Lebrec D. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology 2011;53:683-694 https://doi.org/10.1002/hep.24129
  6. Choi JW, Chung JW, Lee DH, Kim HC, Hur S, Lee M, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol 2018;28:2184-2193 https://doi.org/10.1007/s00330-017-5145-9
  7. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  8. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943 https://doi.org/10.1016/j.jhep.2011.12.001
  9. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-577; quiz 578 https://doi.org/10.1038/ajg.2011.425
  10. Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012;262:1022-1033 https://doi.org/10.1148/radiol.11110817
  11. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007;188:480-488 https://doi.org/10.2214/AJR.05.2079
  12. Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, et al. Radiofrequency ablation of hepatocellular carcinoma as firstline treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014;270:900-909 https://doi.org/10.1148/radiol.13130940
  13. Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol 2008;190:1544-1551 https://doi.org/10.2214/AJR.07.2798
  14. Bezerra AS, D'Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement? AJR Am J Roentgenol 2005;184:1510-1513 https://doi.org/10.2214/ajr.184.5.01841510
  15. Perri RE, Chiorean MV, Fidler JL, Fletcher JG, Talwalkar JA, Stadheim L, et al. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology 2008;47:1587-1594 https://doi.org/10.1002/hep.22219
  16. Lee CM, Jeong WK, Lim S, Kim Y, Kim J, Kim TY, et al. Diagnosis of clinically significant portal hypertension in patients with cirrhosis: splenic arterial resistive index versus liver stiffness measurement. Ultrasound Med Biol 2016;42:1312-1320 https://doi.org/10.1016/j.ultrasmedbio.2016.01.026
  17. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255 https://doi.org/10.1016/S0140-6736(11)61347-0
  18. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 https://doi.org/10.1002/hep.20933
  19. Lang EV, Chen F, Fick LJ, Berbaum KS. Determinants of intravenous conscious sedation for arteriography. J Vasc Interv Radiol 1998;9:407-412 https://doi.org/10.1016/S1051-0443(98)70291-X
  20. Lupescu I, Masala N, Capsa R, Campeanu N, Georgescu SA. CT and MRI of acquired portal venous system anomalies. J Gastrointestin Liver Dis 2006;15:393-398
  21. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004;239:450-458 https://doi.org/10.1097/01.sla.0000118373.31781.f2
  22. Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997;168:719-723 https://doi.org/10.2214/ajr.168.3.9057522
  23. Li C, Hu J, Zhou D, Zhao J, Ma K, Yin X, et al. Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma: application of susceptibility-weighted MR imaging. BMC Cancer 2014;14:590 https://doi.org/10.1186/1471-2407-14-590
  24. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010;254:154-162 https://doi.org/10.1148/radiol.09090304
  25. Kang TW, Rhim H, Lee MW, Kim YS, Choi D, Lim HK. Terminology and reporting criteria for radiofrequency ablation of tumors in the scientific literature: systematic review of compliance with reporting standards. Korean J Radiol 2014;15:95-107 https://doi.org/10.3348/kjr.2014.15.1.95
  26. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol 2014;25:1691-1705.e4 https://doi.org/10.1016/j.jvir.2014.08.027
  27. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104 https://doi.org/10.1053/gast.2003.50018
  28. Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med 2011;3:69-80
  29. Gieling RG, Burt AD, Mann DA. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liver Dis 2008;12:915-937 https://doi.org/10.1016/j.cld.2008.07.001
  30. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928 https://doi.org/10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
  31. Cho KC, Patel YD, Wachsberg RH, Seeff J. Varices in portal hypertension: evaluation with CT. Radiographics 1995;15:609-622 https://doi.org/10.1148/radiographics.15.3.7624566